Mills Wealth Advisors’s AbbVie ABBV Stock Holding History

Mills Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257K	Sell	1,023 -40	-4%	-$8.61K	0.08%	71
2026 Q1	$231K	Buy	1,063 +29	+3%	+$6.43K	0.08%	74
2025 Q4	$236K	Sell	1,034 -10	-1%	-$2.28K	0.09%	62
2025 Q3	$242K	Buy	+1,044	New	+$213K	0.1%	64
2025 Q2	–	Sell	-1,043	Closed	-$219K	–	69
2025 Q1	$219K	Buy	+1,043	New	+$203K	0.12%	58

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mills Wealth Advisors's ABBV Position: Q2 2026 in Review

Mills Wealth Advisors reduced its AbbVie (ABBV) stake by 3.8% in Q2 2026, selling an estimated $8.61K and leaving 1,023 shares worth $257K. The position accounts for 0.08% of the portfolio, ranked #71.

Mills Wealth Advisors first reported a position in ABBV in Q1 2025 and has held it in 5 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Mills Wealth Advisors held 1,023 shares of AbbVie worth $257K as of Q2 2026.
Mills Wealth Advisors sold 40 AbbVie shares in Q2 2026, an estimated $8.61K.
AbbVie made up 0.08% of Mills Wealth Advisors's portfolio in Q2 2026, its #71 holding.
Mills Wealth Advisors first reported a position in AbbVie in Q1 2025 and has held it in 5 quarters since.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mills Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.